Continuous intravenous vasopressin in active upper gastrointestinal bleeding

Area of Science:

• Gastroenterology
• Internal Medicine
• Clinical Pharmacology

Background:

• Upper gastrointestinal bleeding is a significant medical emergency.
• Vasopressin has been considered for managing bleeding, particularly variceal hemorrhage.
• Evidence for its efficacy in continuous intravenous infusion for general upper GI bleeding requires further clarification.

Purpose of the Study:

• To evaluate the efficacy of continuous intravenous vasopressin infusion in controlling active upper gastrointestinal bleeding.
• To compare the outcomes of vasopressin treatment versus placebo in patients with upper gastrointestinal hemorrhage.

Main Methods:

• A randomized controlled trial involving 60 patients with active upper gastrointestinal bleeding.
• Patients received either continuous intravenous vasopressin (40 U/h) or a placebo.
• Bleeding cessation, need for surgery, and mortality were assessed at 6 and 24 hours, and over a 30-month period.

Main Results:

• No significant difference in bleeding cessation rates between the vasopressin and placebo groups at 6 hours (p=0.46) or 24 hours (p=0.30).
• Vasopressin offered no advantage in patients with bleeding from varices.
• Similar rates of surgery (p=0.30), mortality (p=0.51), and transfusion requirements were observed in both groups.

Conclusions:

• Continuous intravenous infusion of vasopressin was ineffective in controlling active upper gastrointestinal bleeding in this patient cohort.
• Vasopressin treatment did not alter key patient outcomes, including the need for surgery or mortality.
• The findings do not support the routine use of continuous intravenous vasopressin for managing upper gastrointestinal hemorrhage.